Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

NCT04418154 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: epirubicin hydrochloride
DRUG: Cyclophosphamide
DRUG: Albumin bound paclitaxel
DRUG: Toripalimab

Sponsor

Fudan University